Corcept Therapeutics, Inc. (CORT)
110.47
-2.91
(-2.57%)
USD |
NASDAQ |
Sep 02, 16:00
111.00
+0.53
(+0.48%)
After-Hours: 17:06
Corcept Therapeutics Research and Development Expense (TTM) : 253.86M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 253.86M |
| March 31, 2026 | 260.44M |
| December 31, 2025 | 254.91M |
| September 30, 2025 | 260.35M |
| June 30, 2025 | 250.84M |
| March 31, 2025 | 249.12M |
| December 31, 2024 | 246.89M |
| September 30, 2024 | 231.29M |
| June 30, 2024 | 217.47M |
| March 31, 2024 | 202.01M |
| December 31, 2023 | 184.35M |
| September 30, 2023 | 166.40M |
| June 30, 2023 | 154.17M |
| March 31, 2023 | 143.72M |
| December 31, 2022 | 130.99M |
| September 30, 2022 | 122.76M |
| June 30, 2022 | 117.56M |
| March 31, 2022 | 112.96M |
| December 31, 2021 | 113.86M |
| September 30, 2021 | 113.62M |
| June 30, 2021 | 119.40M |
| March 31, 2021 | 117.66M |
| December 31, 2020 | 114.76M |
| September 30, 2020 | 110.80M |
| June 30, 2020 | 99.74M |
| Date | Value |
|---|---|
| March 31, 2020 | 94.90M |
| December 31, 2019 | 89.02M |
| September 30, 2019 | 83.50M |
| June 30, 2019 | 79.55M |
| March 31, 2019 | 78.44M |
| December 31, 2018 | 75.25M |
| September 30, 2018 | 70.08M |
| June 30, 2018 | 62.92M |
| March 31, 2018 | 50.25M |
| December 31, 2017 | 40.38M |
| September 30, 2017 | 33.23M |
| June 30, 2017 | 28.59M |
| March 31, 2017 | 26.39M |
| December 31, 2016 | 23.84M |
| September 30, 2016 | 21.45M |
| June 30, 2016 | 18.01M |
| March 31, 2016 | 15.68M |
| December 31, 2015 | 15.42M |
| September 30, 2015 | 15.12M |
| June 30, 2015 | 14.55M |
| March 31, 2015 | 15.46M |
| December 31, 2014 | 18.37M |
| September 30, 2014 | 21.15M |
| June 30, 2014 | 23.26M |
| March 31, 2014 | 23.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Liquidia Corp. | 54.95M |
| Eli Lilly & Co. | 14.60B |
| Abeona Therapeutics, Inc. | 23.37M |
| Indivior Pharmaceuticals, Inc. | 53.00M |
| Crinetics Pharmaceuticals, Inc. | 371.81M |